Product Information
TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) is a generic product labeled by Strides Pharma Inc., priced at $0.6881 per EA under NDC 64380072206. Its NADAC has been published 607 times since Dec 17, 2014.
FDA first approved this application on Jul 22, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380072206
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TACROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA090687FDA Approved
7/22/2014
TE Code
AB
On Market Since
10/5/2020
Pharmacological Classes
Price Statistics
The NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has been published 607 times since Dec 17, 2014, and over the history we have for it it has declined 91.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6881 per EA |
|---|---|
| All-time high | $9.4496 (Feb 11, 2015) |
| All-time low | $0.6505 (Jun 17, 2026) |
| 52-week high | $0.8265 |
| 52-week low | $0.6505 |
| Median price | $1.8619 |
| Average price | $2.4909 |
| Largest weekly change | +172.0% (Dec 13, 2017) |
| Weeks tracked | 607 |
| Tracking since | Dec 17, 2014 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tacrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE), manufactured by Strides Pharma Inc., is $0.6881 per EA (NDC 64380072206), effective Sep 30, 2026.
How has the price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) changed over time?
Over the history we have for it, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has declined 91.0%. It has been tracked across 607 weekly CMS publications since Dec 17, 2014.
What are the highest and lowest recorded NADAC prices for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
Since Dec 17, 2014, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has ranged from a low of $0.6505 (Jun 17, 2026) to a high of $9.4496 (Feb 11, 2015), with a median of $1.8619 per EA.
Are there cheaper alternatives to TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE), is $0.6746 per EA — about 2% below TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE).
Who manufactures TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) (NDC 64380072206) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.